Cipla Shares Rise Over 2.5% After Q1 FY27 Results as Net Profit Jumps 42% QoQ; Motilal Oswal Maintains Neutral Rating

Cipla Ltd. shares gained more than 2.5% in early trade on July 24 after the drugmaker reported stronger sequential earnings for the quarter ended June 30, 2026. Revenue, profitability and operating margins improved from the March quarter, while the company maintained a net cash position of ₹9,494 crore. Although year-on-year profitability remained lower due to a high base, investors responded positively to the improving quarterly performance.

The stock traded at ₹1,428.50, up ₹35.50 (2.55%) around 9:50 AM on the NSE. Following the results, Motilal Oswal Financial Services retained its Neutral rating with a target price of ₹1,420 while increasing its FY27 and FY28 earnings estimates by 4% and 2%, respectively, supported by stronger domestic formulations growth and continued momentum in the South Africa prescription business.

Cipla Q1 FY27 Financial Performance

Cipla reported revenue of ₹7,119 crore, up 9% quarter-on-quarter and 2% year-on-year. Net profit rose 42% sequentially to ₹789 crore from ₹555 crore in Q4 FY26, but declined 39% from ₹1,298 crore reported in the corresponding quarter last year.

EBITDA increased 25% QoQ to ₹1,192 crore, while the EBITDA margin improved to 16.74% from 14.60% in the previous quarter. However, EBITDA and margins remained below the exceptionally strong Q1 FY26 base.

Quarterly Financial Snapshot

Metric	Q1 FY27	Q4 FY26	Q1 FY26	QoQ	YoY
Revenue	₹7,119 Cr	₹6,529 Cr	₹6,969 Cr	+9%	+2%
EBITDA	₹1,192 Cr	₹955 Cr	₹1,817 Cr	+25%	-34%
EBITDA Margin	16.74%	14.60%	25.56%	Improved	Lower
Net Profit	₹789 Cr	₹555 Cr	₹1,298 Cr	+42%	-39%
Net Cash	₹9,494 Cr	-	-	-	-

Why Investors Are Watching Cipla

The June quarter showed a clear recovery from the previous quarter, with higher revenue translating into stronger operating earnings and margin expansion. While annual comparisons remained weak because of a stronger base in Q1 FY26, the company's improving profitability, strong balance sheet and stable international business supported investor sentiment.

The ₹9,494 crore net cash position also gives Cipla financial flexibility to invest in manufacturing, research and development, product launches and potential acquisitions without increasing leverage.

Motilal Oswal's View

According to Motilal Oswal Financial Services, Cipla delivered a largely in-line operational performance, while reported earnings were slightly ahead of expectations due to higher other income.

Brokerage View

Brokerage	Rating	Target Price	Key View
Motilal Oswal Financial Services	Neutral	₹1,420	Raised FY27 EPS by 4% and FY28 EPS by 2%, driven by stronger domestic formulations growth and continued momentum in the South Africa prescription business.

The brokerage expects domestic formulations to remain a key growth driver, while the South Africa prescription portfolio continues to support international earnings. Despite the earnings upgrade, it retained a Neutral recommendation, indicating that much of the expected growth is already reflected in the current valuation.

Business Highlights

India remains Cipla's largest market, with prescription medicines across respiratory, cardiology, oncology, anti-infectives and chronic therapies. The domestic business continues to benefit from rising healthcare spending, increasing diagnosis rates and expanding insurance coverage.

The South Africa prescription business remained another important growth contributor during the quarter, providing geographic diversification and reducing dependence on a single market. Cipla also continues to operate across India, North America, South Africa, Europe and other emerging markets, supported by a diversified portfolio of branded formulations, generic medicines and specialty products.

Share Price Snapshot

Metric	Value
Current Price	₹1,428.50
Gain	₹35.50
Change	+2.55%
Day High	₹1,444.80
Day Low	₹1,390.10
NSE Volume	10.54 lakh shares
Motilal Oswal Target	₹1,420
Net Cash Position	₹9,494 Cr

Industry Outlook

India's pharmaceutical industry continues to benefit from rising demand for chronic therapies, expanding healthcare access and increasing exports to regulated markets. Companies with diversified product portfolios, international operations and strong balance sheets remain better placed to manage pricing pressure and regulatory changes.

Investor Takeaways

The Q1 FY27 results indicate improving operating momentum, supported by 9% revenue growth QoQ, 42% sequential growth in net profit, 25% EBITDA growth, improving margins and a ₹9,494 crore net cash position. Although profitability remained below the high base of the previous year, Motilal Oswal increased its FY27 and FY28 earnings estimates while maintaining a Neutral rating and ₹1,420 target price. Investors are likely to monitor domestic formulations growth, the South Africa business, margin trends and future quarterly earnings over the remainder of FY27.

Why did Cipla shares rise today?

Cipla shares rose more than 2.5% after the company reported 42% quarter-on-quarter growth in net profit, stronger revenue, improving operating margins and maintained a net cash position of ₹9,494 crore.

What were Cipla's Q1 FY27 results?

Cipla reported revenue of ₹7,119 crore, EBITDA of ₹1,192 crore, EBITDA margin of 16.74% and net profit of ₹789 crore during the June quarter.

What is Motilal Oswal's target price for Cipla?

Motilal Oswal Financial Services maintained a Neutral rating on the stock with a target price of ₹1,420, while increasing its FY27 and FY28 earnings estimates.

Why did Motilal Oswal raise earnings estimates?

The brokerage cited stronger domestic formulations growth, continued momentum in the South Africa prescription business and better-than-expected reported earnings supported by higher other income.

How strong is Cipla's balance sheet?

Cipla ended the June quarter with a net cash position of ₹9,494 crore, providing financial flexibility for expansion, research and development, manufacturing investments and strategic opportunities.